Case Report

A Case of Anti-IgLON5 Disease with Aplastic Anemia and Review of The literature

Abstract

Anti-IgLON5 is a neurological condition with neurodegenerative and autoimmune etiology. A 64-year-old man with a 2-year history of aplastic anemia presented with symmetrical parkinsonism, fluctuating consciousness, supranuclear gaze palsy, mild fasciculation, and muscular atrophy. He had disturbances in his sleep cycle and brain MRI. CSF analysis was positive for the IgLON5 antibody. We initiated immunotherapy with high-dose methylprednisolone, intravenous immunoglobulin, and rituximab. The patient showed a mild to moderate response to treatment. We reviewed 29 published case reports regarding anti-Iglon-5 and examined the clinical manifestation. None of the cases showed aplastic anemia, which was the main presentation in our case. All of the patients experienced sleep disturbances, while other symptoms were heterogeneous. Anti-Iglon-5 is usually diagnosed late, leading to a weak prognosis. This study helped us establish a better understanding of the correlation between anti- Iglon5 disease and other autoimmune disorders like anemia.

[1] Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with an- tibodies to IgLON5: a case series, characterisation of the anti- gen, and post-mortem study. Lancet Neurol. 2014;13(6):575- 86.https://doi.org/10.1016/S1474-4422(14)70051-1
[2] Gelpi E, Höftberger R, Graus F, Ling H, Holton JL, Dawson T, et al. Neuropathological criteria of anti-IgLON5-related tauop- athy. Acta Neuropathol. 2016;132(4):531-43.https://doi. org/10.1007/s00401-016-1591-8
[3] Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investiga- tions with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13(1):226.https://doi. org/10.1186/s12974-016-0689-1
[4] Bonello M, Jacob A, Ellul MA, Barker E, Parker R, Jefferson S, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e383.https://doi. org/10.1212/NXI.0000000000000383
[5] Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88(18):1736-43.https://doi.org/10.1212/ WNL.0000000000003887
[6] Cabezudo-García P, Mena-Vázquez N, Estivill Torrús G, Ser- rano-Castro P. Response to immunotherapy in anti-Ig- LON5 disease: A systematic review. Acta Neurol Scand. 2020;141(4):263-70.https://doi.org/10.1111/ane.13207
Files
IssueVol 8 No 6 (2023): November-December QRcode
SectionCase Report(s)
DOI https://doi.org/10.18502/crcp.v8i6.16234
Keywords
Neurology Autoimmune Sleep Disorders Dementia Anti-IgLON5
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Tafakhori A, Ebadi SR, Amirifard H, Karima S, Hasani A, Esmaeili N. A Case of Anti-IgLON5 Disease with Aplastic Anemia and Review of The literature. CRCP. 2024;8(6):252-257.